A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach

Autor: Errington, Niamh, Iremonger, James, Pickworth, Josephine A., Kariotis, Sokratis, Rhodes, Christopher J., Rothman, Alexander MK, Condliffe, Robin, Elliot, Charles A., Kiely, David G., Howard, Luke S., Wharton, John, Thompson, A. A. Roger, Morrell, Nicholas W, Wilkins, Martin R., Wang, Dennis, Lawrie, Allan

Publikováno v: In eBioMedicine July 2021 69

miRNA-140-5p: new avenue for pulmonary arterial hypertension drug development?

Autor: Rothman, Alexander MK, Rowlands, David J, Lawrie, Allan

Publikováno v: Epigenomics; Oct2016, Vol. 8 Issue 10, p1311-1313, 3p

Do Hemodynamic Definitions of Chronic Thromboembolic Pulmonary Hypertension Distinguish Between Distinct Phenotypes of Chronic Thromboembolic Pulmonary Disease?

Autor: Cerrone E; Sheffield Teaching Hospitals NHS Foundation Trust, Pulmonary Vascular Disease Unit, Sheffield, United Kingdom of Great Britain and Northern Ireland., Hameed AG; Sheffield Teaching Hospitals NHS Foundation Trust, Pulmonary Vascular Disease Unit, Sheffield, United Kingdom of Great Britain and Northern Ireland.; The University of Sheffield Department of Infection Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, United Kingdom of Great Britain and Northern Ireland., Kiely DG; Sheffield Teaching Hospitals NHS Foundation Trust, Pulmonary Vascular Disease Unit, Sheffield, United Kingdom of Great Britain and Northern Ireland.; The University of Sheffield Department of Infection Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, United Kingdom of Great Britain and Northern Ireland.; NIHR Sheffield Biomedical Research Centre , Sheffield, United Kingdom of Great Britain and Northern Ireland., Condliffe R; Sheffield Teaching Hospitals NHS Foundation Trust, Pulmonary Vascular Disease Unit, Sheffield, United Kingdom of Great Britain and Northern Ireland.; The University of Sheffield Department of Infection Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, United Kingdom of Great Britain and Northern Ireland., Swift AJ; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, United Kingdom of Great Britain and Northern Ireland.; The University of Sheffield Department of Infection Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, United Kingdom of Great Britain and Northern Ireland.; The University of Sheffield Insigneo Institute for in silico Medicine, Sheffield, South Yorkshire, United Kingdom of Great Britain and Northern Ireland., Rajaram S; Sheffield Teaching Hospitals NHS Foundation Trust, Department of Radiology, Sheffield, United Kingdom of Great Britain and Northern Ireland., Smith I; Sheffield Teaching Hospitals NHS Foundation Trust, Pulmonary Vascular Disease Unit, Sheffield, United Kingdom of Great Britain and Northern Ireland.; The University of Sheffield Department of Infection Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, United Kingdom of Great Britain and Northern Ireland., Hurdman JA; Sheffield Teaching Hospitals NHS Foundation Trust, Pulmonary Vascular Disease Unit, Sheffield, United Kingdom of Great Britain and Northern Ireland.; The University of Sheffield Department of Infection Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, United Kingdom of Great Britain and Northern Ireland., Elliot CA; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, United Kingdom of Great Britain and Northern Ireland.; The University of Sheffield Department of Infection Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, United Kingdom of Great Britain and Northern Ireland., Thompson AAR; The University of Sheffield, Department of Infection, Immunity and Cardiovascular Disease, Sheffield, United Kingdom of Great Britain and Northern Ireland.; Sheffield Teaching Hospitals NHS Foundation Trust, Pulmonary Vascular Disease Unit, Sheffield, United Kingdom of Great Britain and Northern Ireland., Rothman AM; The University of Sheffield, Department of Infection, Immunity and Cardiovascular Disease, Sheffield, United Kingdom of Great Britain and Northern Ireland.; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, United Kingdom of Great Britain and Northern Ireland.; The University of Sheffield, INSIGNEO, Institute for In Silico Medicine, Sheffield, United Kingdom of Great Britain and Northern Ireland., Charalampopoulos A; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, United Kingdom of Great Britain and Northern Ireland.; The University of Sheffield Department of Infection Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, United Kingdom of Great Britain and Northern Ireland; athanasios.charalampopoulos@nhs.net.

Publikováno v: Annals of the American Thoracic Society [Ann Am Thorac Soc] 2024 Oct 15. Date of Electronic Publication: 2024 Oct 15.